Structure Therapeutics (GPCR) Set to Release Quarterly Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Structure Therapeutics to post earnings of ($0.3250) per share and revenue of $50.00 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, analysts expect Structure Therapeutics to post ($1.87) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

Structure Therapeutics Stock Performance

GPCR opened at $20.35 on Wednesday. The stock’s fifty day moving average is $32.29 and its two-hundred day moving average is $48.84. Structure Therapeutics has a 52 week low of $20.30 and a 52 week high of $94.90.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen downgraded Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. Citizens Jmp reaffirmed a “market outperform” rating and issued a $110.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday, August 7th. Finally, Weiss Ratings downgraded shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

About Structure Therapeutics

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.